I agree with a lot of what you're saying about the chart, and I'm a little concerned about this falling back significantly from here. but overall the news was good, just not perfect, and good news was more than baked into price. it's just the usual sell the news biotech story. I think it's shown some strength, because if the news were truly bad, it would already by much lower. the double-whammy of the ABBV news and one downgrade also hurt it a bit. my read on the chart is that the drop was mostly profit taking, as opposed to a true selloff. you don't need to be a chart expert to see that a lot of people did quite well on this stock over the past 6 months, and also that there was a lot of expectation running into these results.
There's a payment for $35M... which is supposedly due but has not been received yet. The $900M is future, based on milestones. It's interesting that they PR'd the other day saying payment is now due, yet nothing has happened since. I'm not saying they won't get it, but... they insinuated that there was a doubt. Might have been unintentional, but still sounds odd.
not short. I hope this year they actually get it done. you'd think if the process has any chance at all, Kodak should be able to pull it off. I do believe a healthy dose of skepticism is in order though. have to admit they've not really been reliable in the past. since the analyst day I think this stock has generally shown some support, and signs of possible accumulation. only time will tell.
It's a growth idea here, not an income idea. trading is more of an income plan. how can I withdraw money to pay bills if I'm waiting 6 months for my stock to "mature" :D
I'll be back, I love the company and hope it does well. It's risky and I trade to pay my bills, so owning a stock that may tank significantly, even short term, is not a smart plan.
haven't followed it lately but last I remember they seemed to be totally screwed by politics. personally, I don't want to trust politicians with my money (if I can help it)
do you think regulators would let them buy it? I don't know much about how they handle biotech acquisitions, but seems like they're trying to go after them for high drug prices and the recent GILD news is an example of competition forcing prices down.
Everyone who bought under 10 either sold already or is selling now
yeah, every biotech that falls is always about to get a buyout offer